Get the Stockscreener App
4.84
5.22%
0.24
Alumis Inc stock is traded at $4.84, with a volume of 692.39K.
It is up +5.22% in the last 24 hours and up +46.22% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.60
Open:
$4.61
24h Volume:
692.39K
Relative Volume:
0.79
Market Cap:
$468.90M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1805
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+1.89%
1M Performance:
+46.22%
6M Performance:
-6.38%
1Y Performance:
-62.45%
1-Day Range:
$4.61
$4.8683
1-Week Range:
$4.33
$5.131
52-Week Range:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.84 | 500.47M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Candlestick Signal Suggests Reversal in Alumis Inc.2025 Retail Activity & Entry Point Strategy Guides - beatles.ru
Analyzing Alumis Inc. with multi timeframe chartsDollar Strength & Entry and Exit Point Strategies - Newser
Alumis Inc. stock daily chart insightsJuly 2025 Decliners & Target Return Focused Picks - Newser
What high frequency data says about Alumis Inc.July 2025 Closing Moves & High Yield Stock Recommendations - Newser
Is Alumis Inc. meeting your algorithmic filter criteriaTrade Entry Report & AI Enhanced Market Trend Forecasts - Newser
Is Alumis Inc. stock a good hedge against inflation2025 Year in Review & Growth Oriented Trade Recommendations - Newser
Predicting Alumis Inc. trend using moving averagesCPI Data & Free Daily Entry Point Trade Alerts - Newser
How high can Alumis Inc. stock goEarnings Recap Report & Daily Profit Focused Screening - Newser
Real time social sentiment graph for Alumis Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Will Alumis Inc. price bounce be sustainableRecession Risk & Verified Entry Point Detection - Newser
Smart tools for monitoring Alumis Inc.’s price actionJuly 2025 Selloffs & Risk Managed Investment Signals - Newser
Reversal indicators forming on Alumis Inc. stock2025 Biggest Moves & Safe Swing Trade Setups - Newser
Alumis Inc. Reports Q2 2025 Earnings and Strategic Advances - TipRanks
Why Alumis Inc. stock attracts strong analyst attention2025 Volume Leaders & Real-Time Stock Entry Alerts - Newser
Equities Analysts Set Expectations for Alumis Q3 Earnings - Defense World
Will breakout in Alumis Inc. lead to full recovery2025 Macro Impact & Low Risk Entry Point Tips - Newser
What makes Alumis Inc. stock price move sharplyQuarterly Portfolio Review & Advanced Swing Trade Entry Plans - Newser
Can momentum traders help lift Alumis Inc.Market Movement Recap & Stepwise Trade Signal Implementation - Newser
Is Alumis Inc. a stock for growth or value investorsJuly 2025 Momentum & Detailed Earnings Play Strategies - classian.co.kr
Morgan Stanley Lowers Alumis (NASDAQ:ALMS) Price Target to $22.00 - Defense World
Can machine learning forecast Alumis Inc. recoveryWeekly Investment Recap & Stock Timing and Entry Methods - Newser
Alumis Inc. Builds Base for Possible ReboundWeekly Risk Summary & Consistent Profit Trading Strategies - metal.it
Alumis Inc. Stock Support and Resistance Levels You Should KnowWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Alumis Inc.: A Biopharma Bargain Amid Clinical Catalysts and Analyst Optimism - AInvest
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Alumis Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
How Alumis Inc. stock performs during market volatilityPortfolio Value Report & Daily Stock Trend Reports - thegnnews.com
Relative strength of Alumis Inc. in sector analysisJuly 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Alumis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Alumis Inc. shares fall 1.36% intraday after reporting Q2 2025 financial results and merger with Acelyrin. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Alumis stock amid post-merger decline - Investing.com
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning - TipRanks
Alumis Misses Q2 Revenue as Costs Jump - AOL.com
Alumis Q2 Revenue Down 5% YoY, Cash to Fund Ops into 2027 - AInvest
Alumis reports Q2 revenue $2.67M, consensus $2.43M - TipRanks
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Alumis Hits Major Milestone in Psoriasis Drug Development, Strengthens Pipeline with $486M War Chest - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Buy” by Brokerages - Defense World
What momentum shifts mean for Alumis Inc.Free Entry Plan for Oversold Reversal Stocks - Newser
Is Alumis Inc. reversing from oversold territoryPredictive Short-Term Market Reversal Alerts - Newser
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - uk.finance.yahoo.com
Alumis Inc.'s (NASDAQ:ALMS) market cap touched US$444m last week, benefiting both retail investors who own 38% as well as institutions - simplywall.st
Alumis Inc. (NASDAQ:ALMS) Stock Position Boosted by Bank of New York Mellon Corp - Defense World
Alumis Inc. Concludes 2025 Annual Stockholders Meeting - The Globe and Mail
How strong is Alumis Inc. company’s balance sheetMassive stock growth - Jammu Links News
What is the dividend policy of Alumis Inc. stockGet alerts on high-potential stock breakouts - Jammu Links News
Should I hold or sell Alumis Inc. stock in 2025Build a portfolio that outperforms consistently - Jammu Links News
When is Alumis Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
What drives Alumis Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
How volatile is Alumis Inc. stock compared to the marketInvest in stocks with strong fundamentals - Jammu Links News
What are analysts’ price targets for Alumis Inc. in the next 12 monthsCapitalize on trading strategies that deliver - Jammu Links News
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):